MSLN and ovarian carcinoma: Mesothelin could potentially be used as an alternative to [18F]FDG to avoid uptake in the gastrointestinal tract, but small peritoneal and pleural metastases that frequently occur in ovarian cancer in particular may be missed, substantially reducing the usability of mesothelin.